Abstract
Data on the use of a combination of antidepressants during pregnancy are inadequate. This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice. The psychiatric diagnoses were determined with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Assessments were performed with the Clinical Global Impression-Improvement Scale and the 17-item Hamilton Rating Scale for Depression. Further studies should be carried out to confirm the positive effects and safety of an additional low-dose mirtazapine in these cases.
MeSH terms
-
Adult
-
Antidepressive Agents, Tricyclic / administration & dosage*
-
Depression / complications
-
Depression / drug therapy*
-
Dose-Response Relationship, Drug
-
Feeding and Eating Disorders / complications
-
Feeding and Eating Disorders / drug therapy
-
Female
-
Humans
-
Mianserin / administration & dosage
-
Mianserin / analogs & derivatives*
-
Mirtazapine
-
Nausea / complications
-
Nausea / drug therapy
-
Panic Disorder / complications
-
Panic Disorder / drug therapy*
-
Pregnancy
-
Pregnancy Complications / drug therapy*
-
Pregnancy Complications / psychology
-
Selective Serotonin Reuptake Inhibitors / administration & dosage*
-
Severity of Illness Index
-
Sleep Initiation and Maintenance Disorders / complications
-
Sleep Initiation and Maintenance Disorders / drug therapy
Substances
-
Antidepressive Agents, Tricyclic
-
Serotonin Uptake Inhibitors
-
Mianserin
-
Mirtazapine